-
1.发明授权公开(公告)号：US11278587B2
公开(公告)日：2022-03-22
申请号：US17239056
申请日：2021-04-23
发明人： Jay Madan , Sandeep Laumas
IPC分类号： A61K38/08 , A61K9/00 , A61P35/00 , A61K39/395 , A61K39/00
摘要： The present invention provides compositions and methods for treating a patient having cancer, as well as methods for potentiating an immune checkpoint inhibitor therapy. The methods comprise administering larazotide or a derivative thereof such as (d)-larazotide to a subject in need, including subjects undergoing checkpoint inhibitor therapy, and subjects scheduled to undergo immune checkpoint inhibitor therapy.
-
2.发明申请公开(公告)号：US20210299481A1
公开(公告)日：2021-09-30
申请号：US17344172
申请日：2021-06-10
发明人： JAY MADAN , ANTHONY BLIKSLAGER , Sandeep Laumas
IPC分类号： A61P1/04 , A61K45/06 , A61K38/08 , A61K35/741
摘要： The present invention provides methods for treating disorders associated with intestinal barrier dysfunction and increased intestinal permeability. The invention involves administering an effective amount larazotide or a larazotide derivative to a subject or a patient in need thereof.
-
3.发明授权公开(公告)号：US11058902B2
公开(公告)日：2021-07-13
申请号：US16484497
申请日：2018-02-12
发明人： Jay P. Madan , Anthony Blikslager , Sandeep Laumas
IPC分类号： A61K38/00 , A61P1/04 , A61K38/08 , A61K45/06 , A61K35/741
摘要： The present invention provides methods for treating disorders associated with intestinal barrier dysfunction and increased intestinal permeability. The invention involves administering an effective amount larazotide or a larazotide derivative to a subject or a patient in need thereof.
-
公开(公告)号：US11608359B2
公开(公告)日：2023-03-21
申请号：US16971739
申请日：2019-02-25
摘要： The present invention provides Larazotide derivative compositions that resist protease degradation, and in various embodiments, do not demonstrate an inverse dose response, and/or can be delivered at higher doses without loss of potency or efficacy, thereby allowing improved therapy and more desirable dosing schedules.
-
-
-
搜索结果
4 条记录 (耗时 0.013 秒)
